The SCNN1G antibody targets the gamma subunit of the epithelial sodium channel (ENaC), encoded by the SCNN1G gene. ENaC, composed of α, β, and γ subunits, regulates sodium transport across epithelial tissues, particularly in the kidneys, lungs, and colon. The γ subunit (SCNN1G) plays a critical role in channel assembly, stability, and activity, influencing fluid and electrolyte homeostasis. Dysregulation of ENaC is linked to disorders like hypertension, pulmonary edema, and cystic fibrosis. SCNN1G antibodies are essential tools for studying ENaC expression, localization, and function in physiological and pathological contexts. They are used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate protein levels in tissue samples or cell models. Research utilizing these antibodies has advanced understanding of ENaC-related mechanisms, including its modulation by hormones (e.g., aldosterone) and involvement in sodium-sensitive diseases. Additionally, SCNN1G antibodies contribute to drug development efforts targeting ENaC overactivity, such as in Liddle syndrome or chronic obstructive pulmonary disease. Their specificity ensures accurate detection of the γ subunit, distinguishing it from other ENaC isoforms, thereby supporting precise molecular and clinical studies.